Overviews

• CROI 2003: When, and With What, to Initiate Antiretroviral Treatment
  Coverage by Cal Cohen, M.D.

• CROI 2003: Management of Metabolic Complications
  Coverage by Pablo Tebas, M.D.

• CROI 2003: Emerging HIV Therapies
  Coverage by David Wohl, M.D.

• Conference Coverage for Everybody: Retrovirus 2003
  Coverage by Myles Helfand with reporting by Bonnie Goldman

• Conference Coverage for Everybody: Retrovirus 2003
  Audio webcast of Search for a Cure's conference recap

February 11, 2003

• New Antiretrovirals
  
  • In-Vitro Characterization of Novel Benzophenone NNRTIs (Oral 6)
    Coverage by Paul E. Sax, M.D.
  • Efficacy and Safety of Tenofovir DF (TDF) Versus Stavudine (d4T) When Used in Combination With Lamivudine and Efavirenz in Antiretroviral-Naive Patients: 96-Week Preliminary Interim Results (Poster 564b)
    Coverage by David Wohl, M.D.

• Epidemiology
  
  • HIV Transmission Risk Behaviors Among HIV-Infected Individuals Released From Prison (Oral 36)
    Coverage by Myles Helfand
  • The Internet and High-Risk Sex Among Men Who Have Sex With Men (Oral 37)
    Coverage by Myles Helfand
  • Sorting Out Serosorting With Sexual Network Methods (Oral 41)
    Coverage by Myles Helfand

• Primary HIV/SIV Infection
  
  • Antiretroviral Resistance Among Patients With Primary HIV Infection in the Southeastern U.S. -- Impact on Treatment Outcome (Poster 502)
    Coverage by Jonathan Schapiro, M.D.

• Resistance Testing: Methodology and Clinical Applications
  
  • Prediction of NRTI Options by Linking Reverse Transcriptase Genotype to Phenotypic Breakpoints (Poster 586)
    Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.

• Resistance to HIV-1 Protease Inhibitors
  
  • Baseline Phenotypic Susceptibility to Tipranavir/Ritonavir Is Retained in Isolates From Patients With Multiple Protease Inhibitor Experience (BI 1182.52) (Poster 596)
    Coverage by Mark A. Wainberg, Ph.D.
  • GW433908 in ART-Naive Subjects: Absence of Resistance at 48 Weeks With Boosted Regimen and APV-Like Resistance Profile With Unboosted Regimen (Poster 598)
    Coverage by Edwin DeJesus, M.D.
  • Comparative Incidence and Temporal Accumulation of PI and NRTI Resistance in HIV-Infected Subjects Receiving Lopinavir/Ritonavir or Nelfinavir as Initial Therapy (Poster 600)
    Coverage by Paul E. Sax, M.D.

• Resistance to HIV-1 Reverse Transcriptase Inhibitors
  
  • NEFA Simplification Trial: Genotypic and Phenotypic Resistance Patterns Among Patients With Virological Failure (Poster 608)
    Coverage by Andrew T. Pavia, M.D.

February 12, 2003

• Immune-Based Therapy
  
  • Immunological and Virological Efficacy of ALVAC-VIH 1433 and HIV Lipopeptides (Lipo-6T) Combined With SC IL-2 in Chronically HIV-Infected Patients -- Results of the ANRS 093 Randomized Study (Oral 62)
    Coverage by Keith Henry, M.D.

• Viral Neuropathogenesis
  
  • HIV-Associated Neuromuscular Weakness Syndrome (Oral 87)
    Coverage by Pablo Tebas, M.D.

• Maternal-Fetal/Pediatrics/Women's Health
  
  • Low Bone Mineral Density in HIV-Infected Women (Oral 102)
    Coverage by Andrew T. Pavia, M.D.
  • HIV Infection and Protease Inhibitor Use Are Not Associated With Reduced Bone Mineral Density in Older HIV-Infected Women (Oral 103)
    Coverage by Andrew T. Pavia, M.D.

• HIV Infection in Women
  
  • Natural History of HIV-1 Infection in Women -- Findings From the Women's Interagency HIV Study (Symposium 115)
    Coverage by Timothy Wilkin, M.D., M.P.H.
  • The Influence of Vitamin A and Hormonal Contraception on HIV Transmission and Disease Progression in Women (Symposium 116)
    Coverage by Timothy Wilkin, M.D., M.P.H.
  • The Impact of Sex/Gender on Antiretroviral Therapy and Its Complications (Symposium 117)
    Coverage by Timothy Wilkin, M.D., M.P.H.

• Relationships Between Drug Levels and Their Effects
  
  • Correlation of Viral Load Reduction and Plasma Levels in Multiple Protease Inhibitor-Experienced Patients Taking Tipranavir/Ritonavir in a Phase IIB Trial: BI 1182.52 (Poster 528)
    Coverage by David Wohl, M.D.
  • Differential Phosphorylation of Zidovudine and Lamivudine (ZDT/3TC) Between Semen and Blood Mononuclear Cells (MCs) in HIV-1-Infected Men (Poster 530)
    Coverage by Edwin DeJesus, M.D.

• Drug-Drug Interactions
  
  • Didanosine and Tenofovir DF Drug-Drug Interaction: Assessment of Didanosine Dose Reduction (Poster 533)
    Coverage by Edwin DeJesus, M.D.
  • Lack of Interaction Between Stavudine Extended-Release Formulation (d4T XR) and Tenofovir Disoproxil Fumarate (TDF) (Poster 534)
    Coverage by Calvin J. Cohen, M.D., M.S.
  • Pharmacokinetic Parameters of Atazanavir/Ritonavir When Combined to Tenofovir in HIV Infected Patients With Multiple Treatment Failures: A Substudy of Puzzle2-ANRS 107 Trial (Poster 537)
    Coverage by Edwin DeJesus, M.D.

• Therapy-Experienced Patients
  
  • Response to a Second Treatment Regimen Following Virologic Failure (Poster 567)
    Coverage by Keith Henry, M.D.

• HBV: Epidemiology, Natural History and Treatment in Co-Infected Patients
  
  • Tenofovir Disoproxil Fumarate and Lamivudine Combination Therapy Compared to Lamivudine Alone for HBV in Therapy-Naive HIV/HBV Co-Infected Patients: 48-Week Interim Results (Poster 825)
    Coverage by David Wohl, M.D.

February 13, 2003

• Pathogenic Mechanisms of HIV Diseases
  
  • Pathogenic Mechanisms of HIV Diseases: The Multifaceted Effects of Virus Replication and Viremia on the Host (Plenary Lecture 119)
    Coverage by Mark A. Wainberg, Ph.D.

• Metabolic and Opportunistic Infectious Complications of HIV Disease
  
  • Exposure to HAART Is Associated With an Increased Risk of Myocardial Infarction: The D:A:D Study (Oral 130)
    Coverage by Judith A. Aberg, M.D.
  • Carotid Intima-Media Thickness in HIV-Infected and Uninfected Adults: ACTG 5078 (Oral 131)
    Coverage by Judith A. Aberg, M.D.

• Antiretroviral Drug Resistance
  
  • Baseline and On-Treatment Susceptibility to Enfuvirtide Seen in TORO 1 and TORO 2 to 24 Weeks (Oral 141)
    Coverage by Jonathan Schapiro, M.D.
  • Effect of Amprenavir (APV) Hypersusceptibility on the Response to APV/Ritonavir (RTV)-Based Therapy in ART-Experienced Adults Selected by Baseline Susceptibility (ESS40006): 24-Week Data (Oral 143)
    Coverage by Pablo Tebas, M.D.

• Topics in Primary HIV Infection
  
  • High Replication Capacity Is Associated With High Baseline Viral Load in Untreated Subjects With Primary HIV Infection (Oral 152)
    Coverage by Judith A. Aberg, M.D.

• Immune Control of HIV: New Insights
  
  • Immune Control and Immune Failure in HIV Infection (Symposium 164)
    Coverage by Keith Henry, M.D.
  • Induction of Potent Anti-HIV Immune Responses In Vivo: Application to Immune Therapy for HIV (Symposium 167)
    Coverage by Keith Henry, M.D.

• Treatment Initiated During Primary HIV Infection
  
  • Is HAART for Primary/Early HIV Infection Associated With Improved Outcomes After Treatment Discontinuation? (Poster 519)
    Coverage by Keith Henry, M.D.
  • The QUEST Cohort: Treatment of Primary HIV Infection (PHI) With Quadruple HAART: Week 48 Preliminary Results (Poster 520)
    Coverage by Andrew T. Pavia, M.D.

• Drug Resistance and Replication Capacity
  
  • Decreased Replication Capacity of HIV-1 Clinical Isolates Containing K65R or M184V RT Mutations (Poster 616)
    Coverage by Calvin J. Cohen, M.D., M.S.

• Resistance: Non-Clade B and Epidemiology
  
  • Prevalence of Mutations Associated With Resistance to Antiretroviral Therapy From 1999-2002 (Poster 635)
    Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.

• Interventions for Prevention or Treatment of Lipodystrophy Syndromes
  
  • Improvements in Body Fat and Mitochondrial (Mt) DNA Levels Are Accompanied by Decreased Adipose Tissue Cell Apoptosis After Replacement of Stavudine Therapy With Either Abacavir or Zidovudine (Poster 728)
    Coverage by Pablo Tebas, M.D.

• Dyslipidemia Associated With Antiretroviral Therapy
  
  • Lipid Changes in a Randomized Comparative Trial of First-Line Antiretroviral Therapy With Regimens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together With Stavudine and Lamivudine (2NN Study) (Poster 752)
    Coverage by Pablo Tebas, M.D.

• Metabolic and Other Complications in HIV-1-Infected Women
  
  • Osteoporosis in Postmenopausal HIV-Positive Women (Poster 766)
    Coverage by Andrew T. Pavia, M.D.

• The Effects of Antiretroviral Therapy During Pregnancy
  
  • PACTG 353: Combined Treatment With HAART (NFV/3TC/ZDV) Increases Thymic Output in HIV-Infected Pregnant Women (Poster 891)
    Coverage by Judith A. Aberg, M.D.

February 14, 2003

• Clinical Trials and Cohorts
  
  • Results of the 2NN Study: A Randomized Comparative Trial of First-Line Antiretroviral Therapy (ART) With Regimens Containing Either Nevirapine (NVP) Alone, Efavirenz (EFV) Alone or Both Drugs Combined, Together With Stavudine and Lamivudine (Oral 176)
    Coverage by Andrew T. Pavia, M.D.
  • The NEAT Study: GW433908 Efficacy and Safety in ART-Naive Subjects: Final 48-Week Analysis (Oral 177)
    Coverage by Keith Henry, M.D.
  • The Context Study: Efficacy and Safety of GW433908/RTV in PI-Experienced Subjects With Virological Failure (24 Week Results) (Oral 178)
    Coverage by Keith Henry, M.D.
  • Tipranavir/Ritonavir (TPV/r) Demonstrates Potent Efficacy in Multiple Protease Inhibitor (PI)-Experienced Patients: BI 1182.52 (Oral 179)
    Coverage by David Wohl, M.D.
  • Does It Matter Where You Came From? Prognosis of Patients Starting Potent Therapy, According to Initial Response (Oral 181)
    Coverage by Judith Feinberg, M.D.

• New Antiretrovirals
  
  • More Regarding Tenofovir Versus d4T in Treatment-Naive Subjects (Poster 564b)
    Coverage by David Wohl, M.D.

  
  

  Return to The Body's coverage of
  The 10th Conference on Retroviruses and Opportunistic Infections.